Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
Clinical trial NCT00975975 · COMPLETED
Trial details
- NCT number
- NCT00975975
- Sponsor
- Indiana University
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2009-09-01
- Primary completion
- 2012-10-01
- Enrollment
- 17
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.